ATE536185T1 - Verfahren zur abschwächung von reaktionen auf hautreizende mittel - Google Patents
Verfahren zur abschwächung von reaktionen auf hautreizende mittelInfo
- Publication number
- ATE536185T1 ATE536185T1 AT02723627T AT02723627T ATE536185T1 AT E536185 T1 ATE536185 T1 AT E536185T1 AT 02723627 T AT02723627 T AT 02723627T AT 02723627 T AT02723627 T AT 02723627T AT E536185 T1 ATE536185 T1 AT E536185T1
- Authority
- AT
- Austria
- Prior art keywords
- immune responses
- compositions
- cd1d
- attenuate
- reactions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27883701P | 2001-03-26 | 2001-03-26 | |
| PCT/US2002/009378 WO2002076401A2 (en) | 2001-03-26 | 2002-03-26 | Method of attenuating reactions to skin irritants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE536185T1 true ATE536185T1 (de) | 2011-12-15 |
Family
ID=23066584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02723627T ATE536185T1 (de) | 2001-03-26 | 2002-03-26 | Verfahren zur abschwächung von reaktionen auf hautreizende mittel |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US7419958B2 (de) |
| EP (1) | EP1372668B1 (de) |
| AT (1) | ATE536185T1 (de) |
| AU (1) | AU2002254396A1 (de) |
| CA (1) | CA2441893C (de) |
| WO (1) | WO2002076401A2 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010051156A1 (en) * | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| CA2441893C (en) * | 2001-03-26 | 2015-01-20 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| EP1539095A1 (de) * | 2002-08-27 | 2005-06-15 | Société des Produits Nestlé S.A. | Prävention oder behandlung von epithelgewebeschäden oder haarausfall |
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US20060140984A1 (en) | 2002-10-25 | 2006-06-29 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
| EP1567113A4 (de) * | 2002-10-24 | 2006-11-08 | G & R Pharmaceuticals Llc | Antimykotische formulierungen |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| ATE539757T1 (de) * | 2004-11-02 | 2012-01-15 | Univ Leland Stanford Junior | Verfahren zur hemmung von nkt-zellen |
| US20070042026A1 (en) * | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
| GB0510463D0 (en) * | 2005-05-23 | 2005-06-29 | Britania Pharmaceuticals Ltd | Improvements in or relating to organic materials |
| US8372040B2 (en) | 2005-05-24 | 2013-02-12 | Chrono Therapeutics, Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| WO2008100912A1 (en) * | 2007-02-12 | 2008-08-21 | The General Hospital Corporation | Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists |
| US8012484B2 (en) * | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
| WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| AU2009205314A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
| WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| AU2010302350B2 (en) | 2009-10-02 | 2015-06-18 | Journey Medical Corporation | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US12661407B2 (en) | 2010-04-08 | 2026-06-23 | Journey Medical Corporation | Compositions, gels and foams with rheology modulators and uses thereof |
| CN111298120A (zh) | 2011-06-24 | 2020-06-19 | 格里生物公司 | 炎性病症的预防和治疗 |
| US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| US20140221320A1 (en) * | 2011-07-08 | 2014-08-07 | The Research Foundation For The State University Of New York | Topical minocycline ointment for suppression of allergic skin responses |
| JP6185575B2 (ja) * | 2012-06-05 | 2017-08-23 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 皮膚炎症性疾患の治療方法 |
| US20140091006A1 (en) * | 2012-09-28 | 2014-04-03 | Anal-Gesic LLC | Single finger and dual finger medication delivery devices, systems and kits; and methods of using the same |
| EP2906576B1 (de) | 2012-10-12 | 2019-09-11 | The Brigham and Women's Hospital, Inc. | Glycosphingolipide und verfahren zur verwendung davon |
| US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
| MX386714B (es) | 2015-01-27 | 2025-03-11 | Lava Therapeutics N V | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 薬剤送達方法及びシステム |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| MX2020012139A (es) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Composiciones y metodos para tratar rosacea y acne. |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| EP3684315B1 (de) * | 2017-09-21 | 2025-03-26 | The Procter & Gamble Company | Absorbierender artikel |
| AU2019279884B2 (en) | 2018-05-29 | 2025-01-30 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用CD1d免疫グロブリン |
| JP2022507660A (ja) | 2018-11-16 | 2022-01-18 | モーニングサイド ベンチャー インベストメンツ リミテッド | 温度によって調節される経皮薬剤送達システム |
| WO2020242715A1 (en) | 2019-05-31 | 2020-12-03 | The Procter & Gamble Company | Absorbent article having a waist gasketing element |
| WO2021092606A1 (en) | 2019-11-04 | 2021-05-14 | The Procter & Gamble Company | Method and apparatus for bonding elastic parts under tension to an advancing carrier |
| US11931233B2 (en) | 2020-05-05 | 2024-03-19 | The Procter & Gamble Company | Absorbent articles including improved elastic panels |
| US12364628B2 (en) | 2020-05-05 | 2025-07-22 | The Procter & Gamble Company | Absorbent articles including front and back waist panels with different stretch characteristics |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0174912A3 (de) * | 1984-09-13 | 1986-06-04 | Ciba-Geigy Ag | Phosphorverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung |
| JPS63255213A (ja) | 1987-04-13 | 1988-10-21 | Kanebo Ltd | 養毛化粧料 |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| JPH0317020A (ja) | 1989-06-14 | 1991-01-25 | Nippon Koutai Kenkyusho:Kk | 抗hiv剤 |
| US5705187A (en) | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
| US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
| US5565207A (en) * | 1990-09-19 | 1996-10-15 | Pola Kasei Kogyo Kabushiki Kaisha | Scalp moisturizer and external skin preparation |
| US5602183A (en) | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
| WO1992017189A1 (en) | 1991-03-29 | 1992-10-15 | The Regents Of The University Of California | Gangliosides with immunosuppressive activity |
| US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5936076A (en) * | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| JP3231079B2 (ja) * | 1992-05-29 | 2001-11-19 | ポーラ化成工業株式会社 | 消炎鎮痛外用剤 |
| US7063844B2 (en) | 1992-12-10 | 2006-06-20 | The Brigham And Women's Hospital, Inc. | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
| US5679347A (en) | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
| DK0751780T3 (da) | 1993-06-21 | 2003-10-13 | Brigham & Womens Hospital | Fremgangsmåder til isolering af CD1-fremviste antigener, vacciner, som omfatter CD1-fremviste antigener, og cellelinier til anvendelse i nævnte fremgangsmåder |
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| US5459037A (en) | 1993-11-12 | 1995-10-17 | The Scripps Research Institute | Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| JP2896321B2 (ja) | 1994-10-27 | 1999-05-31 | 鐘紡株式会社 | β−グルコセレブロシダーゼの活性化方法 |
| US5945409A (en) * | 1995-03-10 | 1999-08-31 | Wilson T. Crandall | Topical moisturizing composition and method |
| US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| US5738856A (en) * | 1995-11-03 | 1998-04-14 | Ocular Research Of Boston, Inc. | Skin care preparation and method |
| FR2742054B1 (fr) * | 1995-12-06 | 1998-01-09 | Synthelabo | Compositions pharmaceutiques contenant un agent anti-inflammatoire et des ceramides vegetales |
| US5776683A (en) | 1996-07-11 | 1998-07-07 | California Pacific Medical Center | Methods for identifying genes amplified in cancer cells |
| WO1998016240A1 (en) * | 1996-10-15 | 1998-04-23 | The Liposome Company, Inc. | Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| EP1520583B1 (de) | 1997-04-10 | 2009-01-28 | Kyowa Hakko Kirin Co., Ltd. | NKT-Zellenaktivatoren, die Alpha-Glycosylceramide enthalten |
| US6063387A (en) * | 1997-04-17 | 2000-05-16 | Elizabeth Arden Co., Division Of Conopco, Inc. | Anhydrous cosmetic composition with ceramides for firming skin |
| FR2765877B1 (fr) * | 1997-07-10 | 1999-09-10 | Oreal | Composition comprenant une dispersion aqueuse de vesicules lipidiques a base de carbamates a chaine cholesteryle, utilisation notamment en cosmetique et nouveaux composes |
| EP1011719A1 (de) | 1997-09-12 | 2000-06-28 | Brigham & Women's Hospital | Synthetische antigene zur cd-1 beschränkte immunantwort |
| TW575420B (en) | 1997-09-22 | 2004-02-11 | Kirin Brewery | Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides |
| CN1112916C (zh) | 1997-12-05 | 2003-07-02 | 科斯莫弗姆有限公司 | 含有游离类鞘氨醇碱和神经酰胺组合的组合物及其用途 |
| CA2316041A1 (en) | 1997-12-30 | 1999-07-08 | Pam Fredman | Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications |
| EP1053243B1 (de) | 1998-02-12 | 2011-03-30 | Emory University | Sphingolipid-derivate und verfahren zu deren verwendung |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| JPH11302155A (ja) | 1998-04-24 | 1999-11-02 | La Shinshia Kk | アトピー性皮膚炎のための皮膚外用剤 |
| US6086898A (en) | 1998-06-23 | 2000-07-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method of converting a Th2-type allergic immune response into a Th1-type immune response |
| JP2003524146A (ja) | 1998-07-09 | 2003-08-12 | ニッコロフ,ブライアン・ジェイ | T細胞上のナチュラルキラーレセプターとそれらに対応するリガンドとの相互作用を変調することにより疾患を治療する方法 |
| DE19841794A1 (de) | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Ceramide und Sphingosine und Derivate) und Mikrobiziden |
| JP2000264825A (ja) * | 1999-03-17 | 2000-09-26 | Fancl Corp | 乳化組成物 |
| JP2000264829A (ja) * | 1999-03-17 | 2000-09-26 | Fancl Corp | 乳化組成物 |
| US20010051156A1 (en) * | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
| US20020071842A1 (en) | 2000-06-05 | 2002-06-13 | Gumperz Jenny E. | Soluble CD1 compositions and uses thereof |
| CN1444648A (zh) | 2000-06-06 | 2003-09-24 | 麒麟麦酒株式会社 | 扩增自然杀伤t细胞的方法 |
| EP1297017B1 (de) | 2000-06-19 | 2012-06-13 | Beth Israel Deaconess Medical Center | Verwendungen und zusammensetzungen von monoklonalen oder polyklonalen antikörpern, die spezifisch für t-zell subpopulationen sind |
| WO2001098317A2 (en) | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| JP3986957B2 (ja) | 2000-08-18 | 2007-10-03 | 三菱電機株式会社 | ランプ用トランス |
| DE10046658A1 (de) | 2000-09-20 | 2002-04-04 | Bosch Gmbh Robert | Induktiver Übertrager und ein Verfahren zu dessen Herstellung |
| US6372236B1 (en) * | 2000-10-18 | 2002-04-16 | Doosan Corporation | Cream composition for skin care |
| DE60131456T2 (de) * | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| IL140537A0 (en) | 2000-12-25 | 2002-02-10 | Hadasit Med Res Service | Educated nk t cells and their uses in the treatment of immune-related disorders |
| CA2441893C (en) * | 2001-03-26 | 2015-01-20 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| US6662434B2 (en) | 2001-04-03 | 2003-12-16 | General Electric Company | Method and apparatus for magnetizing a permanent magnet |
| US8178098B2 (en) * | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| WO2002087556A2 (en) | 2001-04-11 | 2002-11-07 | Atherogenics, Inc. | Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| US20020171538A1 (en) | 2001-05-15 | 2002-11-21 | Kuo-Hsin Su | Vehicle motion detector and control device arrangement |
| US20020171557A1 (en) | 2001-05-18 | 2002-11-21 | Wegener William E. | Security electronic system |
| AU2002327338A1 (en) * | 2001-07-25 | 2003-02-17 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| US20030147865A1 (en) | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
| WO2003092615A2 (en) | 2002-05-01 | 2003-11-13 | Beth Israel Deaconess Medical Center | Use of anti-cd1 antibodies for the modulation of immune responses |
| WO2003105769A2 (en) | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| ATE549064T1 (de) | 2002-06-14 | 2012-03-15 | Us Gov Health & Human Serv | Verfahren zur behandlung und prävention von kolitis, die il-13 und nk-t zellen betrifft |
| US7368142B2 (en) | 2002-08-01 | 2008-05-06 | Renew Life Formulas, Inc. | Natural sweetener |
| EP1539095A1 (de) | 2002-08-27 | 2005-06-15 | Société des Produits Nestlé S.A. | Prävention oder behandlung von epithelgewebeschäden oder haarausfall |
| KR20050062551A (ko) | 2002-09-20 | 2005-06-23 | 기린 비루 가부시키가이샤 | α-글리코실세라미드를 유효 성분으로 하는 C형 간염 바이러스 억제제 |
| AU2003277021A1 (en) | 2002-09-27 | 2004-04-19 | Biomira, Inc. | Glycosylceramide analogues |
| WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| US20040171522A1 (en) | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
| US9717754B2 (en) | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| US20040235162A1 (en) | 2003-03-18 | 2004-11-25 | Kirin Beer Kabushiki Kaisha | Method of preparing immunoregulatory dendritic cells and the use thereof |
| US20050032210A1 (en) | 2003-03-18 | 2005-02-10 | Kirin Beer Kabushiki Kaisha | Method of preparing immuno-regulatory dendritic cells and the use thereof |
| WO2004094444A1 (en) | 2003-03-20 | 2004-11-04 | Brigham Young University | 6'-amino-6'-deoxygalactosylceramides |
| WO2004084874A2 (en) | 2003-03-24 | 2004-10-07 | Brigham And Women's Hospital, Inc. | Mtp inhibitors for inhibiting inflammation |
| EP1653977A2 (de) | 2003-07-17 | 2006-05-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Behandlung von erkrankungen im zusammenhang mit natürlichen killer-t-zellen |
| EP1767216B1 (de) | 2004-06-11 | 2012-07-11 | Riken | Arzneimittel mit regulierendem zellliganden in einem liposom |
| WO2006002132A2 (en) | 2004-06-21 | 2006-01-05 | Exxonmobil Chemical Patents Inc. | Olefin polymerization process |
| ATE539757T1 (de) | 2004-11-02 | 2012-01-15 | Univ Leland Stanford Junior | Verfahren zur hemmung von nkt-zellen |
| WO2006101487A1 (en) | 2005-03-18 | 2006-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Production and therapeutic uses of th1-like regulatory t cells |
| JP5331049B2 (ja) | 2010-04-16 | 2013-10-30 | 株式会社日立製作所 | 回転電機の回転子挿入装置および挿入方法 |
-
2002
- 2002-03-26 CA CA2441893A patent/CA2441893C/en not_active Expired - Fee Related
- 2002-03-26 AU AU2002254396A patent/AU2002254396A1/en not_active Abandoned
- 2002-03-26 AT AT02723627T patent/ATE536185T1/de active
- 2002-03-26 US US10/106,901 patent/US7419958B2/en not_active Expired - Fee Related
- 2002-03-26 EP EP02723627A patent/EP1372668B1/de not_active Expired - Lifetime
- 2002-03-26 WO PCT/US2002/009378 patent/WO2002076401A2/en not_active Ceased
-
2008
- 2008-06-25 US US12/146,386 patent/US20080260680A1/en not_active Abandoned
-
2013
- 2013-10-25 US US14/063,356 patent/US20140286949A1/en not_active Abandoned
-
2015
- 2015-07-17 US US14/802,893 patent/US10226476B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7419958B2 (en) | 2008-09-02 |
| EP1372668A2 (de) | 2004-01-02 |
| EP1372668A4 (de) | 2007-07-25 |
| AU2002254396A1 (en) | 2002-10-08 |
| US20080260680A1 (en) | 2008-10-23 |
| US20140286949A1 (en) | 2014-09-25 |
| US20020165170A1 (en) | 2002-11-07 |
| WO2002076401A2 (en) | 2002-10-03 |
| CA2441893C (en) | 2015-01-20 |
| US20160074423A1 (en) | 2016-03-17 |
| CA2441893A1 (en) | 2002-10-03 |
| EP1372668B1 (de) | 2011-12-07 |
| US10226476B2 (en) | 2019-03-12 |
| WO2002076401A3 (en) | 2003-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1372668A4 (de) | Verfahren zur abschwächung von reaktionen auf hautreizende mittel | |
| JP2004505007A5 (de) | ||
| DE60229971D1 (de) | Zubereitungen zur reizhemmenden rosacea-behandlung | |
| BRPI0407993A (pt) | inibidores de p38 e métodos para uso dos mesmos | |
| WO2003094836A3 (en) | Methods and products for enhancing immune responses using imidazoquinoline compounds | |
| EP0930064A3 (de) | Balneologische Badezusätze, insbesondere in Form einer Brausetablette, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| ATE443523T1 (de) | Verfahren zur behandlung von gelenkentzündung, schmerzen und mobilitätsverlust | |
| ES2135470T3 (es) | Composiciones farmaceuticas y metodos que usan ibobutiramida para tratar trastornos de betaglobina. | |
| PT781281E (pt) | Derivados de beta-carbolina agonistas da melatonina seu processo de preparacao e sua utilizacao a titulo de medicamento | |
| DE3752007D1 (de) | Mittel zur Entziehung von Endprodukten der fortgeschrittenen Glycosylation | |
| DK0759740T3 (da) | Anvendelse af laminarin og oligosaccharider afledt af laminarin inden for kosmetologien og til fremstilling af et medikament beregnet til behandling af huden | |
| TR200500221T2 (tr) | Farmasötik Maddeler Olarak Bisiklik Amino Asitler | |
| CA2182030A1 (fr) | Utilisation d'un antagoniste de bradykinine dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue | |
| ATE318610T1 (de) | Orale zusammensetzungen zur behandlung von kopfhauterkrankungen | |
| ATE77230T1 (de) | Melatoninhaltige mittel sowie deren verwendungen. | |
| BR0211936A (pt) | Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos | |
| AR004326A1 (es) | Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista. | |
| MXPA03011622A (es) | Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas. | |
| BR0116653A (pt) | Medicamento contendo uma poliamina como substância ativa | |
| BR9706889A (pt) | Uso de extratos de ginkgo biloba para a preparação de composições farmacêuticas e processo de tratamento cosmético usando um extrato de ginkgo biloba | |
| RU2394557C1 (ru) | Набор средств для лечения угревой болезни | |
| JP2004514689A (ja) | 表面血流刺激性スキンクリーム | |
| DE60129606D1 (de) | Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| CY1109393T1 (el) | Η χρηση κιγχονης για την παρασκευη ενος φαρμακου που διεγειρει την αγγειογενεση |